Could molecular pathology testing in lung cancer be more cost effective?

Citation for published version:
Walsh, K, Kheng, YC, Oniscu, A, Harrison, D & Wallace, W 2016, 'Could molecular pathology testing in lung cancer be more cost effective?' Journal of Clinical Pathology. DOI: 10.1136/jclinpath-2016-203811

Digital Object Identifier (DOI):
10.1136/jclinpath-2016-203811

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Journal of Clinical Pathology

Publisher Rights Statement:
Author's final peer-reviewed manuscript as accepted for publication.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Could molecular pathology testing in lung cancer be more cost effective?

Kathy Walsh¹, Yuan Chun Kheng¹,², Anca Onisie¹, David Harrison¹,³, William A. Wallace¹

1. Molecular Pathology, Dept. Laboratory Medicine, Royal Infirmary of Edinburgh, Little France Crescent, Old Dalkeith Road, Edinburgh, EH16 4SA, UK.
2. University of Edinburgh Medical School, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB
3. School of Medicine, University of St Andrews, North Haugh, St Andrews KY16 9TF

Correspondence to: Kathy Walsh, Molecular Pathology, Dept. Laboratory Medicine, Royal Infirmary of Edinburgh, Little France Crescent, Old Dalkeith Road, Edinburgh, EH16 4SA, UK, kathy.walsh@nhslothian.scot.nhs.uk, +44 131 242 7141.

KEY WORDS
Lung cancer, Molecular pathology, Cost and pricing

WORD COUNT
1656
ABSTRACT
Aims: EGFR and ALK analysis is routinely undertaken prior to targeted treatment of non-squamous non-small cell lung carcinoma (NSCLC). Increasingly limited resources require molecular pathology services to be cost effective without detriment to patient care.

Methods: Data from an audit of molecular pathology testing in the South East of Scotland Cancer network has been used to explore different testing strategies with the aim of reducing costs; including investigation of TTF1 expression as a negative predictor for EGFR mutations.

Results: TTF1 immunohistochemistry had a high negative predictive value for EGFR mutations (99%). Reflex testing all non-squamous NSCLC had the highest costs whereas limiting testing to those who might be considered for treatment would save 7.5%; a serial testing model could save 32.7%.

Conclusions: Testing only patients being considered for EGFR and ALK inhibitors represented small savings; more significant savings would be achievable if testing algorithms utilized known associations between clinical biomarkers.

INTRODUCTION
Current UK and USA recommendations for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (non-squamous NSCLC) include first line EGFR tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) for tumours with activating EGFR mutations; and ALK inhibitors (crizotinib and ceritinib) for patients whose tumours harbour ALK gene rearrangements.1-3 As a result, predictive EGFR mutation analysis has been carried out by clinical laboratories since 2009 and in 2013 ALK rearrangement analysis was added to the testing algorithm. Studies have shown that in a Caucasian population approximately 10% of NSCLC have EGFR mutations, 2 to 5% have ALK rearrangements, and 35% have KRAS mutations. Although there is no direct therapeutic value in the detection of somatic KRAS mutations it is performed in many laboratories as KRAS mutations are, in the vast majority of samples, mutually exclusive with EGFR and ALK mutations.4

Thyroid transcription factor 1 (TTF1) has, for many years, been used as an immunohistochemical marker to aid the diagnosis of lung adenocarcinoma. Approximately 80% of non-squamous NSCLC requested for molecular pathology testing show positive nuclear staining with TTF1 antibodies.6 Several studies have shown a correlation between TTF1 protein expression and the presence of EGFR mutations (see table 1), indeed TTF1 IHC has been shown to be a good negative predictor of EGFR mutations in western populations; however, this association appears to be less strong in East Asian populations.
Table 1: Studies comparing TTF1 IHC with the presence of EGFR mutations

<table>
<thead>
<tr>
<th>Study</th>
<th>No. samples with TTF1 and EGFR status</th>
<th>Proportion TTF1 positive</th>
<th>No. EGFR mut</th>
<th>No. TTF1 neg</th>
<th>NPV</th>
<th>Population (geographic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vallee et al.</td>
<td>1038</td>
<td>79.0%</td>
<td>3</td>
<td>98.6%</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Vincenten et al.</td>
<td>797</td>
<td>67.9%</td>
<td>9</td>
<td>96.5%</td>
<td>Netherlands</td>
<td></td>
</tr>
<tr>
<td>Krawczyk et al.</td>
<td>727</td>
<td>80.4%</td>
<td>10</td>
<td>93.0%</td>
<td>Poland</td>
<td></td>
</tr>
<tr>
<td>Chatziandreou et al.</td>
<td>595</td>
<td>70.4%</td>
<td>2</td>
<td>98.9%</td>
<td>Greece</td>
<td></td>
</tr>
<tr>
<td>Sheffield et al.</td>
<td>306</td>
<td>77.1%</td>
<td>4</td>
<td>94.3%</td>
<td>Canada</td>
<td></td>
</tr>
<tr>
<td>Somaiah et al.</td>
<td>301</td>
<td>90%</td>
<td>2</td>
<td>93.3%</td>
<td>America</td>
<td></td>
</tr>
<tr>
<td>(pilot and validation)</td>
<td>131</td>
<td>72.5%</td>
<td>1</td>
<td>97.2%</td>
<td>America</td>
<td></td>
</tr>
<tr>
<td>Leary et al.</td>
<td>70</td>
<td>78.6%</td>
<td>0</td>
<td>100%</td>
<td>Britain</td>
<td></td>
</tr>
<tr>
<td>Zhang et al.</td>
<td>1042</td>
<td>87.2%</td>
<td>50</td>
<td>62.4%</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Shanzhi et al.</td>
<td>660</td>
<td>98.5%</td>
<td>1</td>
<td>90%</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Chung et al.</td>
<td>496</td>
<td>89.3%</td>
<td>17</td>
<td>67.92%</td>
<td>Taiwan</td>
<td></td>
</tr>
<tr>
<td>Sun et al.</td>
<td>190</td>
<td>79.5%</td>
<td>6</td>
<td>84.6%</td>
<td>Korea</td>
<td></td>
</tr>
<tr>
<td>Yatabe et al.</td>
<td>95</td>
<td>57.9%</td>
<td>7</td>
<td>82.5%</td>
<td>Japan</td>
<td></td>
</tr>
</tbody>
</table>

There is still debate as to the best approach for molecular pathology testing of lung cancers; some laboratories favour testing all patients with a histologically or cytologically diagnosed non-squamous non-small cell lung cancer, whereas others test only samples from patients being considered for *EGFR* or *ALK* targeted therapy. At present in the UK EGFR tyrosine kinase inhibitors are available as first line therapy to NHS patients with locally advanced or metastatic non-small cell lung cancer and *EGFR* activating mutations in their tumours. Crizotinib has only been recommended for previously treated patients with ALK-positive advanced NSCLC. Although a request based model may require rapid turnaround times in order to meet the clinical need it would be likely to reduce costs by avoiding testing unnecessary cases. This report explores options for improving cost efficiency in lung cancer molecular pathology without impacting patient care.

**METHODS**

The pathology laboratory based at the Royal Infirmary of Edinburgh provides molecular testing in lung cancer for the South East of Scotland cancer network covering NHS Lothian, NHS Borders, NHS Fife and NHS Dumfries and Galloway. A clinical audit was carried out of lung cancer Molecular Pathology requests across the network between January 2011 and March 2014. After histopathology assessment and macrodissection (as required) DNA was extracted from FFPE tissue using the QIAamp DNA FFPE tissue Kit (Qiagen). *EGFR* mutation analysis was carried out using the Therascreen EGFR RGQ PCR kit (Qiagen); mutations in *KRAS* codons 12, 13 and 61 were detected using an in-house Pyrosequencing assay. Samples requiring *ALK* rearrangement analyses were initially screened for ALK protein expression by immunohistochemistry (IHC) using the D5F3 clone (1 in 200 dilution) on a Bond-III system (Leica, UK). Samples positive by ALK IHC were tested for ALK gene rearrangements by fluorescence in situ hybridisation (FISH) using the Vysis ALK
Break Apart FISH Probe Kit (Abbott Molecular). Pearson’s chi-squared test and Fisher’s Exact test were used to explore associations between clinicopathological and molecular parameters. TTF1 IHC was performed, if not already carried out for histological diagnosis, on samples with \( \text{EGFR} \) mutations. TTF1 IHC was performed on a Bond-III using the 8G7G3/1 antibody (M3575, Dako) with 20 minutes retrieval and Leica solution ER2. Sections stained with TTF1 were assessed for the presence of any nuclear staining by a consultant histopathologist specialising in respiratory pathology.

The number and diagnoses of all lung cancer patients registered in the Borders, Dumfries & Galloway, Fife and Lothian Health Boards between April 2013 and March 2014 were supplied by the South East Scotland Cancer Network (SCAN). These data, and the results of the clinical audit, were used to develop models of testing using four algorithms. 1. In the reflex model samples from all patients diagnosed with non-squamous NSCLC, regardless of intention to treat with \( \text{EGFR} \) or \( \text{ALK} \) targeted therapies, would be simultaneously tested for \( \text{EGFR} \), \( \text{KRAS} \) and \( \text{ALK} \) mutations. 2. In the request model only samples from patients with metastatic or locally advanced (stage III and IV) non-squamous NSCLC, i.e. those eligible for treatment with \( \text{EGFR} \) TKIs or \( \text{ALK} \) inhibitors, would be simultaneously tested for \( \text{EGFR} \), \( \text{KRAS} \) and \( \text{ALK} \) mutations. In addition, the number of patients initially diagnosed with stage I or II who would have progressed to stage III or IV was estimated from the clinical audit data and included in the model. 3. The serial testing model was designed to utilise the mutually exclusive relationship between \( \text{EGFR} \), \( \text{KRAS} \) and \( \text{ALK} \) mutations in order to minimise testing. All patients eligible for testing in the request model would be tested for \( \text{KRAS} \) mutations; only those with no mutations would have \( \text{EGFR} \) mutation analysis and only samples with no \( \text{KRAS} \) or \( \text{EGFR} \) mutations would have \( \text{ALK} \) rearrangement analysis. 4. Finally, in the TTF1-serial model all patients selected with the request model would be initially tested for TTF1 and \( \text{ALK} \) rearrangements; given the limited data available this model does not assume a correlation between TTF1 expression and \( \text{ALK} \) rearrangements. Only TTF1 positive \( \text{ALK} \) negative samples would have \( \text{KRAS} \) mutation analysis and only those with no \( \text{KRAS} \) mutations would be tested for \( \text{EGFR} \) mutations. The cost of testing using each model was estimated using the CMD Impact Business Planning Tool developed by the Royal College of Pathologists, Cancer Research UK and the Association of the British Pharmaceutical Industry (https://www.rcpath.org/cmd-impact.html). The estimated annual cost of each model was represented as a proportion of the cost of the request model.

RESULTS
Between January 2011 and March 2014 there were 710 requests for lung cancer molecular pathology testing; of those suitable for testing 10.5% had \( \text{EGFR} \) mutations, 36.5% had \( \text{KRAS} \) mutations, 2.3% had \( \text{ALK} \) gene rearrangements, and 79.4% showed positive staining for TTF1. No samples were found to have co-occurring \( \text{EGFR} \), \( \text{KRAS} \) or \( \text{ALK} \) mutations. Although positive TTF1 IHC was not predictive for the presence of \( \text{EGFR} \) mutations (positive predictive value 13.4%, \( n=461 \)) no samples with \( \text{EGFR} \) mutations were negative for TTF1 expression. After additional TTF1 IHC 117 specimens with \( \text{EGFR} \) mutations were positive for TTF1 nuclear staining and 1 showed only cytoplasmic staining and was therefore considered negative; equating to a negative predictive value (NPV) of 99.05%
Four hundred patients with histopathology/ cytopathological samples were diagnosed with adenocarcinoma or non-small cell lung carcinoma between April 2013 and March 2014; of those 370 were stage III or IV and therefore eligible for EGFR TKI or ALK inhibitor therapy. Based on these figures, the annual cost of lung cancer molecular pathology testing by the request model was estimated to be 92.5% of that of the reflex model. Testing by the serial model was estimated to cost only 67.3% of the request model. If TTF1 were fully validated as a negative predictive biomarker the cost of testing could be reduced to 62.5% of the reflex model (summarised in table 2).

<table>
<thead>
<tr>
<th>Model</th>
<th>Cohort</th>
<th>Tests carried out</th>
<th>Cost relative to reflex model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reflex</td>
<td>All non-squamous NSCLC</td>
<td><em>EGFR, ALK &amp; KRAS</em> simultaneously</td>
<td>100%</td>
</tr>
<tr>
<td>Request</td>
<td>Stage III or IV non-squamous NSCLC</td>
<td><em>KRAS; KRAS neg &gt; EGFR; KRAS &amp; EGFR neg &gt; ALK</em></td>
<td>92.5%</td>
</tr>
<tr>
<td>Serial</td>
<td>TTF1-serial</td>
<td>TTF1 &amp; ALK; TTF1 pos &amp; ALK neg &gt; KRAS; TTF1 pos &amp; KRAS neg &gt; EGFR</td>
<td>67.3%</td>
</tr>
</tbody>
</table>

Neg= no mutation detected, Pos= positive expression of protein

**DISCUSSION**

In our cohort TTF1 IHC had a high negative predictive value (NPV) for *EGFR* mutations supporting the association previously reported in several studies with Caucasian populations,6 7 9 12 although this correlation seems to be weaker in East Asian populations.13 15-17 Two studies used a scoring system to determine TTF1 status which may have reduced the number of positive samples and therefore lowered the NPV.7 16 Our study was carried out in a clinical diagnostic setting and any nuclear staining, even focal staining, was considered positive for TTF1. One sample from a total of 118 *EGFR* mutation positive patients showed only cytoplasmic staining with the TTF1 antibody; upon further investigation this biopsy, which had a p.(Gly719X) *EGFR* mutation, was taken post chemo-radiation. A previous specimen taken pre-treatment was TTF1 positive, however since several years had elapsed between the two samples it was not possible to determine if the latter biopsy was a recurrence or a second primary tumour. Unfortunately, there was too little tissue remaining in the pre-treatment sample to perform *EGFR* mutation analysis.

Many clinical laboratories are experiencing increasing pressures to reduce costs; where funding is restricted algorithms must supply the most cost effective use of limited resources without compromising clinical utility and the welfare of patients. The saving represented by only testing patients eligible for treatment with targeted therapies (the request model) would be easily achievable in most clinical laboratories without any detrimental effect on patient care; a proposal supported by data from another institution.18 In reality NHS Lothian employs a system between the reflex and request models and accepts requests from oncologists if a patient is being considered...
for treatment or from histopathologists if the diagnostic sample confirms distant metastatic disease.

Currently there is no direct therapeutic impact of KRAS nevertheless KRAS mutation status in non-squamous NSCLC does have some value, since a large proportion of tumours carry mutations their detection ensures, particularly in samples with a low proportion of neoplastic cells, that the appropriate tissue has been tested. Withdrawing KRAS analysis would reduce costs by 18% compared to the reflex model. However, stratifying the cohort using the serial model, including KRAS analysis, would allow a much greater saving; a 32.7% reduction compared to the reflex model. Recent European Society for Medical Oncology (ESMO) guidelines do not recommend KRAS mutation analysis in a serial model due to the effect on turnaround times and the potential waste of tumour material. However KRAS mutation analysis can be performed in less than a day and in our lab is already frequently available before performing EGFR analysis. On average lung cancer molecular pathology testing in NHS Lothian is reported in 3.8 working days; the addition of an extra day for KRAS mutation analysis would have little impact on patient treatment and falls well within the 10 working days recommended by the joint guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Where specimen size, and therefore DNA yield, is limiting samples should proceed straight to EGFR analysis to avoid the risk of exhausting the sample. Laboratories whose primary method is a multiplex assay, for example next generation sequencing (NGS), would not benefit from the serial model; but for many labs NGS is not an option and will, for the foreseeable future, continue to carry out single genes analyses.

The value of TTF1 IHC may not be limited to cost efficiency, if an initial specimen was considered insufficient for molecular analysis the TTF1 status may help determine the value of subjecting a patient to a procedure to obtain a repeat sample. Although promising there is, as yet, too little data on the association between TTF1 IHC and EGFR to fully support its use as a negative predictor for EGFR mutations. Further audits by molecular pathology laboratories could elucidate this relationship and help confirm or refute the use of this readily available histopathology biomarker as a screening tool prior to EGFR mutation analysis.

REFERENCES


